Associations - erlotinib

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval bevacizumab + erlotinib Sensitive : A1	bevacizumab + erlotinib Sensitive: A1 - Approval bevacizumab + erlotinib Sensitive : A1
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval erlotinib + Aybintio (bevacizumab biosimilar) Sensitive : A1	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval erlotinib + Aybintio (bevacizumab biosimilar) Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1	erlotinib + ramucirumab Sensitive: A1 - Approval erlotinib + ramucirumab Sensitive : A1
EGFR G719X	Non Small Cell Lung Cancer	EGFR G719X	Non Small Cell Lung Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Chordoma	No biomarker	Chordoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR S768I	Non Small Cell Lung Cancer	EGFR S768I	Non Small Cell Lung Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2	erlotinib + ramucirumab Sensitive: A2 - Guideline erlotinib + ramucirumab Sensitive : A2
No biomarker	Vulvar Cancer	No biomarker	Vulvar Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab + erlotinib Resistant: A2 - Guideline bevacizumab + erlotinib Resistant : A2	bevacizumab + erlotinib Resistant: A2 - Guideline bevacizumab + erlotinib Resistant : A2
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	erlotinib Resistant: A2 - Guideline erlotinib Resistant : A2	erlotinib Resistant: A2 - Guideline erlotinib Resistant : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2	bevacizumab + erlotinib Sensitive: A2 - Guideline bevacizumab + erlotinib Sensitive : A2
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR overexpression	Esophageal Squamous Cell Carcinoma	EGFR overexpression	Esophageal Squamous Cell Carcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B
EGFR exon 19 mutation	Non Small Cell Lung Cancer	EGFR exon 19 mutation	Non Small Cell Lung Cancer	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B	erlotinib + ramucirumab Sensitive: B - Late Trials erlotinib + ramucirumab Sensitive : B

erlotinib

Associations
(235)

Associations
(235)

erlotinib

Associations(235)

Associations(235)

Associations
(235)

Associations
(235)